{"product_id":"art-of-drug-synthesis-wiley-series-on-drug-synthesis-9780471752158","title":"Art of Drug Synthesis Wiley Series on Drug","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other disciplines come together to produce successful medicines. The authors have compiled a collection of 21 representative categories of drugs, from which they have selected as examples many of the best-selling drugs on the market today.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e“This is a most topical and useful short primer on estab1ished drugs and their synthesis.” (\u003ci\u003eAmerican Journal of Therapeutics\u003c\/i\u003e, June 2009)  \u003cp\u003e\"The book is very felicitous and closes a gap in the literature by covering the subject of drug development in this particular way.\" (\u003ci\u003eAngewandte Chemie\u003c\/i\u003e, June 23, 2008)\u003c\/p\u003e \u003cp\u003e\"This book is a very entertaining read.\" (\u003ci\u003eChemMedChem\u003c\/i\u003e, 2008, 3)\u003c\/p\u003e \u003cp\u003e\"The editors and contriubting authros have certainly provided a most useful book for the medicinal and organic chemistry community.\" (\u003ci\u003eJournal of Medicinal Chemistry\u003c\/i\u003e, March 2008)\u003c\/p\u003e \u003cp\u003e\"Where I see the book being very useful is as a starting point for student seminars or discussion groups... Also, it is highly illuminating just to dip into for a browse and to marvel at some of the excellent chemistry that goes on in the pharmaceutical industry.\" (\u003ci\u003eChemistry World\u003c\/i\u003e, January 2008)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eForeword xi\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003eContributors xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY 1\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJohn A. Lowe, III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Hurdles in the Drug Discovery Process 2\u003c\/p\u003e \u003cp\u003e1.3 The Tools of Medicinal Chemistry 3\u003c\/p\u003e \u003cp\u003e1.4 The Role of Synthetic Chemistry in Drug Discovery 6\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 PROCESS RESEARCH: HOW MUCH? HOW SOON? 11\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eNeal G. Anderson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 11\u003c\/p\u003e \u003cp\u003e2.2 Considerations for Successful Scale-up to Tox Batches and Phase I Material 15\u003c\/p\u003e \u003cp\u003e2.3 Considerations for Phase 2 Material and Beyond 16\u003c\/p\u003e \u003cp\u003e2.4 Summary 26\u003c\/p\u003e \u003cp\u003eI CANCER AND INFECTIOUS DISEASES\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) 31\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 32\u003c\/p\u003e \u003cp\u003e3.2 Synthesis of Exemestane 35\u003c\/p\u003e \u003cp\u003e3.3 Synthesis of Anastrozole 36\u003c\/p\u003e \u003cp\u003e3.4 Synthesis of Letrozole 37\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) 39\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eChris Limberakis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 40\u003c\/p\u003e \u003cp\u003e4.2 Levofloxacin 47\u003c\/p\u003e \u003cp\u003e4.3 Moxifloxacin 57\u003c\/p\u003e \u003cp\u003e4.4 Gemifloxacin 60\u003c\/p\u003e \u003cp\u003e4.5 Garenoxacin (T-3811): A Promising Clinical Candidate 64\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) 71\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAndrew S. Bell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 72\u003c\/p\u003e \u003cp\u003e5.2 Synthesis of Itraconazole 74\u003c\/p\u003e \u003cp\u003e5.3 Synthesis of Fluconazole 76\u003c\/p\u003e \u003cp\u003e5.4 Synthesis of Voriconazole 77\u003c\/p\u003e \u003cp\u003e5.5 Synthesis of Fosfluconazole 80\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS 83\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eArthur Harms\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 84\u003c\/p\u003e \u003cp\u003e6.2 Synthesis of Nevirapine 85\u003c\/p\u003e \u003cp\u003e6.3 Synthesis of Efavirenz 87\u003c\/p\u003e \u003cp\u003e6.4 Synthesis of Delavirdine Mesylate 90\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) 95\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eDouglas S. Johnson and Jie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 95\u003c\/p\u003e \u003cp\u003e7.1.1 Relenza 97\u003c\/p\u003e \u003cp\u003e7.1.2 Tamiflu 97\u003c\/p\u003e \u003cp\u003e7.2 Synthesis of Oseltamivir Phosphate (Tamiflu) 99\u003c\/p\u003e \u003cp\u003e7.3 Synthesis of Zanamivir (Relenza) 110\u003c\/p\u003e \u003cp\u003eII CARDIOVASCULAR AND METABOLIC DISEASES\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES 117\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJin Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 117\u003c\/p\u003e \u003cp\u003e8.2 Synthesis of Rosiglitazone 121\u003c\/p\u003e \u003cp\u003e8.3 Synthesis of Pioglitazone 122\u003c\/p\u003e \u003cp\u003e8.4 Synthesis of Muraglitazar 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION 129\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLarry Yet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 130\u003c\/p\u003e \u003cp\u003e9.2 Losartan Potassium 132\u003c\/p\u003e \u003cp\u003e9.3 Valsartan 134\u003c\/p\u003e \u003cp\u003e9.4 Irbesartan 135\u003c\/p\u003e \u003cp\u003e9.5 Candesartan Cilexetil 136\u003c\/p\u003e \u003cp\u003e9.6 Olmesartan Medoxomil 137\u003c\/p\u003e \u003cp\u003e9.7 Eprosartan Mesylate 138\u003c\/p\u003e \u003cp\u003e9.8 Telmisartan 139\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 LEADING ACE INHIBITORS FOR HYPERTENSION 143\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eVictor J. Cee and Edward J. Olhava\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 144\u003c\/p\u003e \u003cp\u003e10.2 Synthesis of Enalapril Maleate 146\u003c\/p\u003e \u003cp\u003e10.3 Synthesis of Lisinopril 147\u003c\/p\u003e \u003cp\u003e10.4 Synthesis of Quinapril 148\u003c\/p\u003e \u003cp\u003e10.5 Synthesis of Benazepril 150\u003c\/p\u003e \u003cp\u003e10.6 Synthesis of Ramipril 151\u003c\/p\u003e \u003cp\u003e10.7 Synthesis of Fosinopril Sodium 154\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION 159\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eDaniel P. Christen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 160\u003c\/p\u003e \u003cp\u003e11.2 Synthesis of Nifedipine (Adalat) 162\u003c\/p\u003e \u003cp\u003e11.3 Synthesis of Felodepine (Plendil) 163\u003c\/p\u003e \u003cp\u003e11.4 Synthesis of Amlodipine Besylate (Norvasc) 164\u003c\/p\u003e \u003cp\u003e11.5 Synthesis of Azelnidipine (Calblock) 165\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS 169\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eJeffrey A. Pfefferkorn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 170\u003c\/p\u003e \u003cp\u003e12.2 Synthesis of Fluvastatin (Lescol) 171\u003c\/p\u003e \u003cp\u003e12.3 Synthesis of Rosuvastatin (Crestor) 174\u003c\/p\u003e \u003cp\u003e12.4 Synthesis of Pitavastatin (Livalo) 177\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) 183\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eStuart B. Rosenblum\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 183\u003c\/p\u003e \u003cp\u003e13.2 Discovery Path to Ezetimibe 184\u003c\/p\u003e \u003cp\u003e13.3 Synthesis of Ezetimibe (Zetia) 187\u003c\/p\u003e \u003cp\u003eIII CENTRAL NERVOUS SYSTEM DISEASES\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION 199\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMarta Pineiro-Nunez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 200\u003c\/p\u003e \u003cp\u003e14.2 Synthesis of Venlafaxine 203\u003c\/p\u003e \u003cp\u003e14.3 Synthesis of Milnacipran 205\u003c\/p\u003e \u003cp\u003e14.4 Synthesis of Duloxetine 207\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON 215\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePeter R. Guzzo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 216\u003c\/p\u003e \u003cp\u003e15.2 Synthesis of Zolpidem 217\u003c\/p\u003e \u003cp\u003e15.3 Synthesis of Zaleplon 219\u003c\/p\u003e \u003cp\u003e15.4 Synthesis of Eszopiclone 220\u003c\/p\u003e \u003cp\u003e15.5 Synthesis of Indiplon 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Alpha2Delta LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) 225\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePo-Wai Yuen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 225\u003c\/p\u003e \u003cp\u003e16.2 Synthesis of Gabapentin 227\u003c\/p\u003e \u003cp\u003e16.3 Synthesis of Pregabalin 234\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) 241\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eDavid L. Gray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 242\u003c\/p\u003e \u003cp\u003e17.2 Synthesis of Amphetamine 244\u003c\/p\u003e \u003cp\u003e17.3 Synthesis of Methylphenidate 247\u003c\/p\u003e \u003cp\u003e17.4 Synthesis of Atomoxetine 253\u003c\/p\u003e \u003cp\u003eReferences 257\u003c\/p\u003e \u003cp\u003eIndex 261\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402669138263,"sku":"9780471752158","price":109.76,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780471752158.jpg?v=1730481175","url":"https:\/\/bookcurl.com\/products\/art-of-drug-synthesis-wiley-series-on-drug-synthesis-9780471752158","provider":"Book Curl","version":"1.0","type":"link"}